Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (995)	10/6/1999 12:31:00 PM
From: scaram(o)uche	Respond to of 4974

This is fun....... I've pointed at these guys before, one of a new breed of "phenotyping" companies....... Wednesday October 6, 8:03 am Eastern Time Company Press Release SOURCE: Sangamo BioSciences, Inc. Sangamo BioSciences Expands Agreement With Pfizer POINT RICHMOND, Calif., Oct. 6 /PRNewswire/ -- Sangamo BioSciences, Inc. announced today at the ING Barings Genomics/Drug Discovery 99 Conference in New York that it has expanded its collaborative research agreement with Pfizer, Inc. Under the expanded agreement, Pfizer will purchase additional Universal GeneTools(TM) from Sangamo for use in the identification and validation of novel gene targets for drug discovery. Financial terms were not disclosed. ''Pfizer was one of the first companies to evaluate our zinc finger protein-based GeneTools(TM) in their target validation programs and the collaborative nature of our relationship has been very important and productive,'' said Edward Lanphier, President and Chief Executive Officer of Sangamo. ''We are delighted that Pfizer has found Sangamo's Universal GeneTools(TM) useful in their research and are pleased to have the opportunity to expand our relationship.'' Sangamo's Universal GeneTools(TM) technology platform enables the rational design and rapid generation of highly specific zinc finger DNA binding protein (ZFP) transcription factors that can selectively recognize and regulate any target gene or DNA sequence. These engineered ZFPs are being used to accelerate the functional analysis of newly discovered genes and the validation of clinically relevant gene targets thereby providing pharmaceutical researchers with a powerful tool in the search for novel, more effective therapeutics. Expressed sequence tags (ESTs), the short DNA sequences derived from genomic research, contain sufficient information for the effective design of a ZFP capable of regulating the expression of a target gene in both cell-based and transgenic animal model systems. Sangamo BioSciences, a privately held biotechnology company, is also developing its ZFP technology platform for human therapeutic, plant genomic and clinical diagnostic product applications. Universal Gene Regulation embodies the application of ZFPs to the development of pharmaceutical products that act through the selective and highly specific regulation of genes implicated in human disease. Similarly, the Company is employing the ZFP platform in plant agriculture to accelerate the discovery and functional analysis of new gene traits and the generation of novel transgenic plants. Finally, Sangamo's Universal Gene Identification is being developed to exploit opportunities in the emerging field of clinical gene diagnostics. For more information see our website at www.sangamo.com. SOURCE: Sangamo BioSciences, Inc.